About: Antiviral effects of probiotic metabolites on COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antiviral effects of probiotic metabolites on COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antiviral effects of probiotic metabolites on COVID-19
Creator	Kamal, Mohammad Al-Abbasi, Fahad Al-Malki, Abdulrahman Altayb, Hisham Anwar, Firoz Kumar, Vikas
topic	covid:6653211e4fa19ee33df4b66a6d7a81f6b9d70795#this
Source	Medline; PMC
abstract	SARS coronavirus (COVID-19) is a real health challenge of the 21st century for scientists, health workers, politicians, and all humans that has severe cause epidemic worldwide. The virus exerts its pathogenic activity through by mechanism and gains the entry via spike proteins (S) and Angiotensin-Converting Enzyme 2 (ACE2) receptor proteins on host cells. The present work is an effort for a computational target to block the residual binding protein (RBP) on spike proteins (S), Angiotensin-Converting Enzyme 2 (ACE2) receptor proteins by probiotics namely Plantaricin BN, Plantaricin JLA-9, Plantaricin W, Plantaricin D along with RNA-dependent RNA polymerase (RdRp). Docking studies were designed in order to obtain the binding energies for Plantaricin metabolites. The binding energies for Plantaricin W were −14.64, −11.1 and −12.68 for polymerase, RBD and ACE2 respectively comparatively very high with other compounds. Plantaricin W, D, and JLA-9 were able to block the residues (THR556, ALA558) surrounding the deep grove catalytic site (VAL557) of RdRp making them more therapeutically active for COVID-19. Molecular dynamics studies further strengthen stability of the complexes of plantaricin w and SARS-CoV-2 RdRp enzyme, RBD of spike protein, and human ACE2 receptor. The present study present multi-way options either by blocking RBD on S proteins or interaction of S protein with ACE2 receptor proteins or inhibiting RdRp to counter any effect of COVID-19 by Plantaricin molecules paving a way that can be useful in the treatment of COVID-19 until some better option will be available. Communicated by Ramaswamy H. Sarma
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1080/07391102.2020.1775123
bibo:pmid	32475223
has license	no-cc
sha1sum (hex)	6653211e4fa19ee33df4b66a6d7a81f6b9d70795
schema:url	https://doi.org/10.1080/07391102.2020.1775123
resource representing a document's title	Antiviral effects of probiotic metabolites on COVID-19
has PubMed Central identifier	PMC7298884
has PubMed identifier	32475223
schema:publication	J Biomol Struct Dyn
resource representing a document's body	covid:6653211e4fa19ee33df4b66a6d7a81f6b9d70795#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/6653211e4fa19ee33df4b66a6d7a81f6b9d70795
is schema:about of	named entity 'binding' named entity 'high' named entity 'proteins' named entity 'inhibiting' named entity 'humans' named entity 'human' named entity 'protein' named entity 'active' named entity 'binding energies' named entity 'RBD' named entity 'Antiviral' named entity 'BINDING' named entity 'MULTI' named entity 'ENERGIES' named entity 'PROTEIN ' named entity 'HUMANS' named entity 'METABOLITES' named entity 'RDRP' named entity 'probiotics' named entity 'century' named entity 'COVID-19' named entity 'residual' named entity 'RBD' named entity 'RNA-dependent RNA polymerase' named entity 'complexes' named entity 'scientists' named entity 'RdRp' named entity 'COVID-19' named entity 'epidemic' named entity 'RdRp' named entity 'ACE2' named entity 'ACE2 receptor' named entity 'SARS-CoV-2' named entity 'binding protein' named entity 'spike proteins' named entity 'metabolites' named entity 'ACE2' named entity 'RBP' named entity 'RNA-dependent RNA polymerase' named entity 'binding energies' named entity 'SARS-CoV-2' named entity 'catalytic site' named entity 'RBD' named entity 'solvation' named entity 'Molecular dynamics' named entity 'COVID-19' named entity 'Root-mean-square deviation' named entity 'protein' named entity 'MOE' named entity 'COVID-19' named entity 'Remdesivir' named entity 'transmissibility' named entity 'Molecular Operating Environment' named entity 'probiotic' named entity 'lactic acid' named entity 'active site' named entity 'enzyme' named entity 'Lactobacillus plantarum' named entity 'RdRp' named entity 'antioxidant activity' named entity 'China' named entity 'host cell' named entity 'host cell' named entity 'tissue tropism' named entity 'immunomodulatory' named entity 'RdRp' named entity 'COVID' named entity 'protein' named entity 'RdRp' named entity 'glycoprotein' named entity 'peptides' named entity 'probiotic' named entity 'protein' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software